Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ AXUD1 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA577146
Description
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Axin, an important regulator of beta-catenin, is frequently mutated in human hepatocellular carcinomas (HCCs), and transduction of the wild-type Axin gene (AXIN1) induces apoptosis in HCC cells as well as in colon cancer cells. A novel gene, AXUD1 (AXIN1 up-regulated), has enhanced expression in response to exogenously expressed AXIN1. It is expressed in all human tissues examined, most abundantly in lung, placenta, skeletal muscle, pancreas and leukocytes. Data suggests that AXUD1 may have a tumor-suppressor function in those organs.
Specifications
AXUD1 | |
Polyclonal | |
Unconjugated | |
CSRNP1 | |
4931429D10Rik; AXIN1 up-regulated 1; Axin-1 up-regulated gene 1 protein; AXUD1; Csrnp1; CSRNP-1; cysteine and serine rich nuclear protein 1; cysteine/serine-rich nuclear protein 1; cysteine-serine-rich nuclear protein 1; DKFZp566F164; FAM130B; Protein URAX1; Taip3; TAIP-3; TGF-beta induced apoptosis protein 3; TGF-beta-induced apoptosis protein 3; URAX1; URAX1 protein | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
215418, 363165, 64651 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.2 | |
P59054, Q96S65 | |
CSRNP1 | |
Recombinant full length Human AXUD1. | |
100 μL | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction